Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

88.84 -0.19 (-0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Thera

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Axsome Therapeutics's Earnings: A Preview
Via Benzinga
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Long Term Investor Alert: Lawsuit Against Directors Filed
San Diego, CA -- (SBWIRE) -- 02/17/2023 -- An investor in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) filed a lawsuit against certain directors of Axsome Therapeutics, Inc. over alleged breaches... 
Via SBWire
Meta Platforms Layoffs 2023: What to Know as Facebook Preps More Job Cuts
Meta Platforms (META) layoffs are a hot topic among traders Monday as the Facebook parent company reportedly considering more job cuts. 
Via InvestorPlace
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug
Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug. 
Via InvestorPlace
The Latest Analyst Ratings for Axsome Therapeutics
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $1,900 Today
Via Benzinga
Here's How Much $100 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
The company only just gained approval for its depression drug in August. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These companies could grow in prominence in the coming years. 
Via The Motley Fool
3 Surefire Growth Stocks You Can Buy Right Now
Maybe there's no such thing as a sure thing. But these stocks could come close. 
Via The Motley Fool
3 Stocks That Could Soar Whether There's a New Bull Market or Not
These stocks could enjoy their own bull markets regardless of what the overall market does. 
Via The Motley Fool
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The Ultimate Growth Stocks to Buy With $300 Right Now
These three companies should deliver inflation-busting long-term growth. 
Via The Motley Fool
2 Promising New Growth Stocks to Watch in 2023
These stocks have plenty of room to run. 
Via The Motley Fool
3 Unstoppable Stocks to Keep Buying in 2023
These companies have what it takes to drive long-term share performance. 
Via The Motley Fool
2 Stocks That Could Double Your Money in 2023
These biotechs could crush the market, but there is more to the story. 
Via The Motley Fool
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
These stocks look cheap if you take a long-term view. 
Via The Motley Fool
5 Top Stocks to Buy to Start the New Year Right
This may be the easiest of your New Year's resolutions. And it could pay off big. 
Via The Motley Fool
How Is The Market Feeling About Axsome Therapeutics?
Axsome Therapeutics's (NASDAQ:AXSM) short percent of float has fallen 7.06% since its last report. The company recently reported that it has 7.37 million shares sold short, which is 20.81% of all... 
Via Benzinga
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles
Energy and medical plays top the 100 Best Stocks of 2022. It makes sense, given world events that shifted the first-quarter playing field. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
2 Growth Stocks to Buy Heading Into 2023
These biotechs are far from having achieved their full potential. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Got $5,000? 2 Unstoppable Stocks to Buy and Hold
These businesses are growing and can be excellent places to make a sizable investment right now. 
Via The Motley Fool
Better Buy: Moderna vs Axsome
Revenue prospects look promising for both of these biotech companies. 
Via The Motley Fool
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.